Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Potent, selective, and subunit‐dependent activation of TRPC5 channels by a xanthine derivative

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background and Purpose

          The TRPC1, TRPC4, and TRPC5 proteins form homotetrameric or heterotetrameric, calcium‐permeable cation channels that are involved in various disease states. Recent research has yielded specific and potent xanthine‐based TRPC1/4/5 inhibitors. Here, we investigated the possibility of xanthine‐based activators of these channels.

          Experimental Approach

          An analogue of the TRPC1/4/5 inhibitor Pico145, AM237, was synthesized and its activity was investigated using HEK cells overexpressing TRPC4, TRPC5, TRPC4–C1, TRPC5–C1, TRPC1:C4 or TRPC1:C5 channels, and in A498 cells expressing native TRPC1:C4 channels. TRPC1/4/5 channel activities were assayed by measuring intracellular concentration of Ca 2+ ([Ca 2+] i) and by patch‐clamp electrophysiology. Selectivity of AM237 was tested against TRPC3, TRPC6, TRPV4, or TRPM2 channels.

          Key Results

          AM237 potently activated TRPC5:C5 channels (EC 50 15–20 nM in [Ca 2+] i assay) and potentiated their activation by sphingosine‐1‐phosphate but suppressed activation evoked by (−)‐englerin A (EA). In patch‐clamp studies, AM237 activated TRPC5:C5 channels, with greater effect at positive voltages, but with lower efficacy than EA. Pico145 competitively inhibited AM237‐induced TRPC5:C5 activation. AM237 did not activate TRPC4:C4, TRPC4–C1, TRPC5–C1, TRPC1:C5, and TRPC1:C4 channels, or native TRPC1:C4 channels in A498 cells, but potently inhibited EA‐dependent activation of these channels with IC 50 values ranging from 0.9 to 7 nM. AM237 (300 nM) did not activate or inhibit TRPC3, TRPC6, TRPV4, or TRPM2 channels.

          Conclusions and Implications

          This study suggests the possibility for selective activation of TRPC5 channels by xanthine derivatives and supports the general principle that xanthine‐based compounds can activate, potentiate, or inhibit these channels depending on subunit composition.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: found
          • Article: not found

          TRP channels.

          The TRP (Transient Receptor Potential) superfamily of cation channels is remarkable in that it displays greater diversity in activation mechanisms and selectivities than any other group of ion channels. The domain organizations of some TRP proteins are also unusual, as they consist of linked channel and enzyme domains. A unifying theme in this group is that TRP proteins play critical roles in sensory physiology, which include contributions to vision, taste, olfaction, hearing, touch, and thermo- and osmosensation. In addition, TRP channels enable individual cells to sense changes in their local environment. Many TRP channels are activated by a variety of different stimuli and function as signal integrators. The TRP superfamily is divided into seven subfamilies: the five group 1 TRPs (TRPC, TRPV, TRPM, TRPN, and TRPA) and two group 2 subfamilies (TRPP and TRPML). TRP channels are important for human health as mutations in at least four TRP channels underlie disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            TRP channels as cellular sensors.

            TRP channels are the vanguard of our sensory systems, responding to temperature, touch, pain, osmolarity, pheromones, taste and other stimuli. But their role is much broader than classical sensory transduction. They are an ancient sensory apparatus for the cell, not just the multicellular organism, and they have been adapted to respond to all manner of stimuli, from both within and outside the cell.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers.

              This article updates the guidance published in 2015 for authors submitting papers to British Journal of Pharmacology (Curtis et al., 2015) and is intended to provide the rubric for peer review. Thus, it is directed towards authors, reviewers and editors. Explanations for many of the requirements were outlined previously and are not restated here. The new guidelines are intended to replace those published previously. The guidelines have been simplified for ease of understanding by authors, to make it more straightforward for peer reviewers to check compliance and to facilitate the curation of the journal's efforts to improve standards.
                Bookmark

                Author and article information

                Contributors
                kmuraki@dpc.agu.ac.jp
                r.bon@leeds.ac.uk
                Journal
                Br J Pharmacol
                Br. J. Pharmacol
                10.1111/(ISSN)1476-5381
                BPH
                British Journal of Pharmacology
                John Wiley and Sons Inc. (Hoboken )
                0007-1188
                1476-5381
                06 September 2019
                October 2019
                06 September 2019
                : 176
                : 20 ( doiID: 10.1111/bph.v176.20 )
                : 3924-3938
                Affiliations
                [ 1 ] School of Chemistry University of Leeds Leeds UK
                [ 2 ] Department of Discovery and Translational Science, Leeds Institute of Cardiovascular and Metabolic Medicine University of Leeds Leeds UK
                [ 3 ] Discovery Sciences, R&B Biopharmaceuticals AstraZeneca Alderley Park UK
                [ 4 ] Laboratory of Cellular Pharmacology, School of Pharmacy Aichi‐Gakuin University Nagoya Japan
                Author notes
                [*] [* ] Correspondence

                Dr Robin S. Bon, Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, LIGHT Building, Clarendon Way, University of Leeds, Leeds LS2 9JT, UK.

                Email: r.bon@ 123456leeds.ac.uk

                Professor Katsuhiko Muraki, Laboratory of Cellular Pharmacology, School of Pharmacy, Aichi‐Gakuin University, 1‐100 Kusumoto, Chikusa, Nagoya 464‐8650, Japan.

                Email: kmuraki@ 123456dpc.agu.ac.jp

                [*]

                Aisling Minard and Claudia C. Bauer contributed equally.

                Author information
                https://orcid.org/0000-0002-0767-6877
                https://orcid.org/0000-0003-1733-3680
                Article
                BPH14791 2018-BJP-1631-RP.R2
                10.1111/bph.14791
                6811774
                31277085
                62ad739a-d13e-428e-8f95-424120b58d96
                © 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 21 December 2018
                : 27 June 2019
                : 02 July 2019
                Page count
                Figures: 7, Tables: 0, Pages: 15, Words: 7064
                Funding
                Funded by: Biotechnology and Biological Sciences Research Council , open-funder-registry 10.13039/501100000268;
                Award ID: 1568094 (iCASE studentship)
                Award ID: BB/P020208/1
                Award ID: BB/L015676/1
                Funded by: Wellcome Trust , open-funder-registry 10.13039/100004440;
                Award ID: 102174/B/13/Z
                Award ID: 110044/Z/15/Z
                Funded by: AstraZeneca , open-funder-registry 10.13039/100004325;
                Award ID: 1568094 (industrial partner on BBSRC iCASE studentship)
                Funded by: British Heart Foundation , open-funder-registry 10.13039/501100000274;
                Award ID: PG/19/2/34084
                Categories
                Research Paper
                Research Papers
                Custom metadata
                2.0
                October 2019
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.0 mode:remove_FC converted:24.10.2019

                Pharmacology & Pharmaceutical medicine
                Pharmacology & Pharmaceutical medicine

                Comments

                Comment on this article